Biochanin

Biochanin

SCHEMBL29410271

COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 1.00
MAPT P10636 7/20 1.00
MEN1 O00255 6/20 1.00
KMT2A Q03164 6/20 1.00
SMN1; SMN2 Q16637 6/20 1.00
NPC1 O15118 6/20 1.00
ALDH1A1 P00352 6/20 1.00
CYP3A4 P08684 6/20 1.00
TP53 P04637 5/20 1.00
HPGD P15428 5/20 1.00
CYP2C9 P11712 4/20 1.00
CYP2C19 P33261 4/20 1.00
MAOA P21397 4/20 1.00
HSD17B10 Q99714 4/20 1.00
KDM4E B2RXH2 4/20 1.00
CYP2D6 P10635 3/20 1.00
NFKB1 P19838 3/20 1.00
NFKB2 Q00653 3/20 1.00
RELA Q04206 3/20 1.00
MAOB P27338 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biochanin SCHEMBL61258 1.00 RAB9A (1.00) RAB9AMAPTMEN1KMT2ASMN1; SMN2
4',7-Dimethoxy-5-Hydroxygenistein SCHEMBL572108 0.93 RAB9A (1.00) RAB9AMAPTMEN1KMT2ASMN1; SMN2
Formononetin SCHEMBL6312014 0.91 MAPT (0.83) RAB9AMAPTMEN1KMT2ASMN1; SMN2
Formononetin SCHEMBL4223418 0.91 MAPT (0.83) RAB9AMAPTMEN1KMT2ASMN1; SMN2
Genistein SCHEMBL18241115 0.89 MEN1 (0.89) RAB9AMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL12238015 0.88 SMN1; SMN2 (0.79) RAB9AMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL12892701 0.88 RAB9A (0.81) RAB9AMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL26145339 0.88 KDM4E (0.85) RAB9AMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL13481416 0.88 MEN1 (0.79) RAB9AMAPTMEN1KMT2ASMN1; SMN2
Prunetin SCHEMBL29612430 0.88 ALDH2 (1.00) RAB9AMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108488-A1 PROCESS FOR PREPARING BIOCHANIN A-LOADED HYDROGEL FOR PROMOTING WOUND HEALING IN DIABETIC PATIENTS ALGHAMDI ABEER S (SA) 2026-04-23 US claimed
EP-3346842-B1 STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME NOVONESIS PLANT BIOSOLUTIONS AS (DK) 2026-03-25 EP claimed
WO-2025229086-A1 ADHESIVE COSMETIC COMPOUNDS AND USES THEREOF SKINOSIVE (FR) 2025-11-06 WO claimed
EP-4125866-B1 BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES UNIV REGENSBURG (DE) 2025-10-08 EP claimed
EP-4101437-B1 BACTERIOSTATIC COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF SHENZHEN EULIKAN BIOTECHNOLOGY CO LTD (CN) 2025-06-11 EP claimed
CN-119110720-A Cosmetic composition 布茨公司 2024-12-10 CN claimed
EP-3520785-B1 USES OF BACTERIOSTATIC AGENT FORMULA IN PREPARING COMPOSITION FOR VAGINAL USE AND COMPOSITION FOR VAGINAL USE SHENZHEN EULIKAN BIOTECHNOLOGY CO LTD (CN) 2024-07-17 EP claimed
CN-116990401-A Method for analyzing three-white soup ingredients by using ultrahigh resolution liquid chromatography-mass spectrometry technology 安徽中医药大学 2023-11-03 CN claimed
EP-3449943-B1 A PHARMACEUTICAL COMPOSITION FOR IMPROVING OR PREVENTING PROGRESSION OF CHRONIC KIDNEY DISEASE FRIMLINE PRIVATE LTD (IN) 2022-08-31 EP claimed
US-12629351-B2 HDAC inhibitors for idiopathic pulmonary fibrosis and other lung inflammatory disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860)) (IN) 2026-05-19 US disclosed
US-20260108488-A1 PROCESS FOR PREPARING BIOCHANIN A-LOADED HYDROGEL FOR PROMOTING WOUND HEALING IN DIABETIC PATIENTS ALGHAMDI ABEER S (SA) 2026-04-23 US disclosed
EP-3906040-B1 COMBINATION OF CIMICIFUGA AND PETASITES EXTRACTS FOR ANTICANCER THERAPY AND PROPHYLAXIS ZELLER MAX SOEHNE AG (CH) 2026-04-08 EP disclosed
EP-4208443-B1 HDAC INHIBITORS FOR IDIOPATHIC PULMONARY FIBROSIS AND OTHER LUNG INFLAMMATORY DISORDERS COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER REGN OF SOC A (IN) 2025-11-26 EP disclosed
US-12478605-B2 Biochanin a derivatives for treatment of BEST1-related retinopathies UNIVERSITÄT REGENSBURG (DE) 2025-11-25 US disclosed
EP-2825624-B2 WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND METHOD OF MAKING SAME MONOSOL LLC (US) 2022-07-27 EP disclosed
EP-2838811-B2 POWDERED POUCH AND METHOD OF MAKING SAME MONOSOL LLC (US) 2022-06-29 EP disclosed
CN-109415321-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-06-17 CN disclosed
WO-2022123428-A2 POLYMERIC MEMBRANE 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-06-16 WO disclosed
WO-2022049599-A1 HDAC INHIBITORS FOR IDIOPATHIC PULMONARY FIBROSIS AND OTHER LUNG INFLAMMATORY DISORDERS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860)) (IN) 2022-03-10 WO disclosed
WO-2022046522-A1 SUPPLEMENT THAT ENHANCES INTRACELLULAR CONCENTRATION OF BIOACTIVE MOLECULES THROUGH INHIBITION OF MULTIDRUG RESISTANT (MDR) EFFLUX PUMPS Brilliant Lab LLC (US) 2022-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12629351-B2 HDAC inhibitors for idiopathic pulmonary fibrosis and other lung inflammatory disorders HDAC8, HDAC7, HDAC1 RAB9A 1164/4885MAPT 4646/4885MEN1 4874/4885
US-20260108488-A1 PROCESS FOR PREPARING BIOCHANIN A-LOADED HYDROGEL FOR PROMOTING WOUND HEALING IN DIABETIC PATIENTS VEGFA, HMOX2, HMOX1 RAB9A 2806/4885MAPT 4057/4885MEN1 4872/4885
US-12478605-B2 Biochanin a derivatives for treatment of BEST1-related retinopathies SORBS1, SLC5A6, SLC20A1 RAB9A 1919/4885MAPT 1330/4885MEN1 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.